Health & Fitness
Health and Fitness
Health and Fitness
Tue, November 26, 2024Mon, November 25, 2024Thu, November 14, 2024Tue, November 12, 2024Sat, June 10, 2017Sat, June 3, 2017Wed, May 31, 2017Wed, May 17, 2017Fri, May 12, 2017Thu, May 11, 2017Tue, May 9, 2017Thu, May 4, 2017Thu, April 20, 2017Fri, April 14, 2017Thu, March 23, 2017Fri, March 17, 2017Thu, March 9, 2017Sat, March 4, 2017Fri, March 3, 2017Thu, March 2, 2017Wed, February 15, 2017Mon, February 13, 2017Wed, February 8, 2017Thu, February 2, 2017Fri, January 13, 2017Wed, January 11, 2017Wed, January 4, 2017Fri, December 16, 2016Thu, December 15, 2016Mon, December 12, 2016Thu, December 8, 2016Wed, November 23, 2016Mon, November 14, 2016Sun, November 13, 2016Wed, November 9, 2016Thu, November 3, 2016Wed, November 2, 2016Mon, October 17, 2016Sat, October 8, 2016Thu, October 6, 2016Wed, October 5, 2016Mon, October 3, 2016Fri, September 30, 2016Thu, September 29, 2016Tue, September 27, 2016Mon, September 26, 2016Fri, September 23, 2016Thu, September 22, 2016Wed, September 21, 2016Tue, September 20, 2016Mon, September 19, 2016Sun, September 18, 2016Fri, September 16, 2016Thu, September 15, 2016Wed, September 14, 2016Mon, September 12, 2016Fri, September 9, 2016Thu, May 9, 2013Wed, May 8, 2013Tue, May 7, 2013Mon, May 6, 2013Sun, May 5, 2013Fri, May 3, 2013Thu, May 2, 2013Wed, May 1, 2013Tue, April 30, 2013Mon, April 29, 2013Sun, April 28, 2013Fri, April 26, 2013Thu, April 25, 2013Insys Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option
Published in Health and Fitness on Tuesday, May 7th 2013 at 7:15 GMT by Market Wire
May 07, 2013 09:59 ET
Insys Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option
PHOENIX, AZ--(Marketwired - May 7, 2013) - Insys Therapeutics, Inc. (
Wells Fargo Securities, LLC and JMP Securities LLC acted as joint book-running managers for the offering. Oppenheimer & Co. acted as co-manager.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A registration statement relating to the offering has been filed with, and declared effective by, the Securities and Exchange Commission. The offering is being made only by means of a final prospectus, which is part of the effective registration statement. Copies of the final prospectus may be obtained by contacting Wells Fargo Securities, LLC, 1525 West W.T. Harris Boulevard, NC0675, Charlotte, NC 28262, Attn: Capital Markets Client Support, telephone: 1-800-326-5897 or email: [ cmclientsupport@wellsfargo.com ]; or JMP Securities LLC, Attn: Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111 (415-835-8985).
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. We have two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. We market Subsys through our incentive-based, cost-efficient commercial organization of approximately 67 sales professionals. Our lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be our second branded supportive care product, if approved.
